Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 4.5
edited by manuelmenendez
on 2025/01/27 23:00
Change comment: There is no comment for this version
To version 21.1
edited by manuelmenendez
on 2025/01/28 00:30
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,9 +2,10 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= Neurodiagnoses =
5 += //A new tridimensional diagnostic framework for neurodegenerative diseases// =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
7 +This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 +We aim to create a structured, interpretable, and scalable diagnostic tool.
8 8  )))
9 9  )))
10 10  
... ... @@ -12,21 +12,71 @@
12 12  (((
13 13  (% class="col-xs-12 col-sm-8" %)
14 14  (((
15 -= What can I find here? =
16 += What is this about and what can I find here? =
16 16  
17 -* `/docs`: Documentation and contribution guidelines.
18 -* `/code`: Machine learning pipelines and scripts.
19 -* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports.
18 +== **Overview** ==
20 20  
21 -= Who has access? =
20 +The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on:
22 22  
22 +* **Axis 1**: Etiology (genetic or other causes of diseases).
23 +* **Axis 2**: Molecular Markers (biomarkers).
24 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 +
26 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
27 +
28 +
29 +This methodology enables:
30 +
31 +* Greater precision in diagnosis.
32 +* Integration of incomplete datasets using AI-driven probabilistic modeling.
33 +* Stratification of patients for personalized treatment.
34 +
35 +== **Diagnostic Axes** ==
36 +
37 +* (((
38 +**Axis 1: Etiology**
39 +
40 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
41 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
42 +* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
43 +)))
44 +* (((
45 +**Axis 2: Molecular Markers**
46 +
47 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
48 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
49 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
50 +)))
51 +* (((
52 +**Axis 3: Neuroanatomoclinical**
53 +
54 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
55 +* //Examples//: Hippocampal atrophy correlating with memory deficits.
56 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
57 +)))
58 +
59 +== **Applications** ==
60 +
61 +This system enhances:
62 +
63 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
64 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
65 +
66 +== Who has access? ==
67 +
23 23  We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
24 24  
25 -== How to Contribute: ==
70 +== How to Contribute ==
26 26  
27 27  * Access the `/docs` folder for guidelines.
28 28  * Use `/code` for the latest AI pipelines.
29 29  * Share feedback and ideas in the wiki discussion pages.
75 +
76 +== Key Objectives ==
77 +
78 +* Develop interpretable AI models for diagnosis and progression tracking.
79 +* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
80 +* Foster collaboration among neuroscientists, AI researchers, and clinicians.
30 30  )))
31 31  
32 32  
... ... @@ -36,11 +36,13 @@
36 36  {{toc/}}
37 37  {{/box}}
38 38  
39 -== Key Objectives: ==
90 +== Main contents ==
40 40  
41 -* Develop interpretable AI models for diagnosis and progression tracking.
42 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
43 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
44 -
92 +* `/docs`: Documentation and contribution guidelines.
93 +* `/code`: Machine learning pipelines and scripts.
94 +* `/data`: Sample datasets for testing.
95 +* `/outputs`: Generated models, visualizations, and reports.
96 +* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
97 +* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
45 45  )))
46 46  )))
tridimensional.png
Author
... ... @@ -1,0 +1,1 @@
1 +XWiki.manuelmenendez
Size
... ... @@ -1,0 +1,1 @@
1 +149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -No
1 +Yes
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Levels
... ... @@ -1,0 +1,1 @@
1 +view
Users
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,0 +1,1 @@
1 +Allow
Groups
... ... @@ -1,0 +1,1 @@
1 +XWiki.XWikiAllGroup
Levels
... ... @@ -1,0 +1,1 @@
1 +view